TMCI - NASDAQ

Treace Medical Concepts, Inc.

TMCI·NASDAQ

$3.40

-5.6%

HealthcareMedical - Devices

Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$220.57M

EPS-0.9300

P/E Ratio-3.66

Earnings Date08/06/2026

190.58M

Assets

-12%

3Y+20.0%

5Y+356.0%

10Y+541.0%

103.25M

Total Liabilities

-1%

3Y+5.0%

5Y+152.0%

10Y+289.0%

87.33M

Total Equity

-23%

3Y+44.0%

5Y+11154.0%

10Y+2663.0%

Treace Medical Concepts, Inc. Funding & Solvency Profile

TMCI · NASDAQ

Current Assets

Cash & Cash Equivalents10.71M

Net Receivables42.16M

Inventory36.03M

Other Current Assets5.50M

Total Current Assets132 M

Non-Current Assets

Property, Plant & Equipment37.37M

Goodwill & Intangible Assets19.94M

Long-Term Investments0.00

Other Non-Current Assets1.22M

Total Non-Current Assets39 M

Total Assets

190.58M

Financial Health Analysis

Current Ratio

4.31x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

1.18x

Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.

Working Capital

101 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

69% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Treace Medical Concepts, Inc. Balance Sheet

TMCI • NASDAQ

Treace Medical Concepts, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	10.7M	11.4M	13M	19.5M	105.8M	18.1M	12.1M
Short-Term Investments	37.7M	64.3M	110.2M	61.8M	0.0	0.0	0.0
Cash & Short-Term Investments	48.4M	75.7M	123.2M	81.3M	105.8M	18.1M	12.1M
Net Receivables	42.2M	40.8M	38.1M	29.2M	18.6M	14.5M	10.4M
Accounts Receivables	42.2M	40.8M	38.1M	29.2M	18.6M	14.5M	10.4M
Inventory	36M	39.3M	29.2M	19.3M	10.6M	7.8M	5.6M
Prepaids	0.0	0.0	0.0	0.0	3M	593K	458K
Other Current Assets	5.5M	5.7M	7.9M	3.6M	0.0	0.0	0.0
Total Current Assets	132.1M	161.4M	198.4M	133.4M	138M	41M	28.6M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	37.4M	34.4M	31.6M	25.5M	2.8M	829K	1.1M
Goodwill	12.8M	12.8M	12.8M	0.0	0.0	0.0	0.0
Intangible Assets	7.1M	8.1M	9M	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	19.9M	20.9M	21.8M	0.0	0.0	0.0	0.0
Other Non-Current Assets	1.2M	407K	146K	146K	0.0	0.0	0.0
Total Non-Current Assets	58.5M	55.7M	53.5M	25.6M	2.8M	829K	1.1M
Total Assets	190.6M	217.1M	251.9M	159M	140.8M	41.8M	29.7M
LIABILITIES
CURRENT LIABILITIES
Total Payables	6.7M	10.5M	11.8M	8.7M	4.1M	2.3M	931K
Accounts Payable	6.7M	10.5M	11.8M	8.7M	4.1M	2.3M	931K
Accrued Expenses	0.0	21.8M	7.5M	13.6M	14.2M	7.5M	6.4M
Short Term Debt	0.0	0.0	0.0	0.0	0.0	1.8M	0.0
Capital Lease Obligations (Current)	0.0	413K	1.4M	339K	0.0	0.0	0.0
Other Current Liabilities	23.9M	2.2M	24.2M	7.7M	0.0	1K	0.0
Total Current Liabilities	30.6M	34.9M	45M	30.2M	18.2M	11.6M	7.3M
NON-CURRENT LIABILITIES
Long Term Debt	14M	53.3M	53M	52.7M	29.4M	29.2M	19.2M
Other Non-Current Liabilities	58.6M	37K	37K	0.0	173K	244K	0.0
Total Non-Current Liabilities	72.6M	69.3M	68.9M	68.3M	29.5M	29.4M	19.2M
Capital Lease Obligations	0.0	16.3M	17.3M	15.9M	0.0	0.0	0.0
Total Liabilities	103.2M	104.2M	114M	98.5M	47.7M	41M	26.6M
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	-281K	-13K	0.0	0.0	0.0	0.0
Preferred Stock	0.0	0.0	0.0	0.0	0.0	7.9M	7.9M
Common Stock	64K	62K	62K	55K	45K	28K	28K
Additional Paid-In Capital	0.0	303M	272M	145.2M	134.9M	14.2M	12.9M
Retained Earnings	-249M	-190M	-134.2M	-84.7M	-41.9M	-21.4M	-17.7M
Accumulated Other Comprehensive Income/Loss	72K	97K	163K	-27K	0.0	0.0	0.0
Other Total Stockholders' Equity	336.2M	0.0	0.0	0.0	0.0	0.0	0.0
Total Stockholders' Equity	87.3M	112.9M	137.9M	60.5M	93.1M	776K	3.2M
Total Equity	87.3M	112.9M	137.9M	60.5M	93.1M	776K	3.2M
SUMMARY
Total Liabilities & Equity	190.6M	217.1M	251.9M	159M	140.8M	41.8M	29.7M
Total Investments	37.7M	64.3M	110.2M	61.8M	0.0	0.0	0.0
Total Debt	14M	69.7M	70.3M	68.6M	29.4M	31M	19.2M
Net Debt	3.3M	58.3M	57.3M	49.1M	-76.5M	12.9M	7.1M
Shares Outstanding	63,173,126	63,173,126	63,173,126	63,173,126	63,173,126	63,173,126	63,173,126

SEC Filings

TMCI - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 20, 2026	May 19, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 08, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 08, 2026	May 08, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 09, 2026	April 08, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 06, 2026	April 03, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 27, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 27, 2026	February 27, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 13, 2026	January 13, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 18, 2025	December 16, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 06, 2025	September 30, 2025	2025	View Filing

Showing 1 to 10 of 75 filings

Related Guides

Blog Categories

Continue your TMCI research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.